NASDAQ:SYRS Syros Pharmaceuticals (SYRS) Stock Forecast, Price & News $3.73 +0.03 (+0.81%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$3.67▼$3.8150-Day Range$2.51▼$4.0852-Week Range$2.42▼$11.50Volume25,861 shsAverage Volume87,956 shsMarket Capitalization$76.82 millionP/E RatioN/ADividend YieldN/APrice Target$15.75 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Syros Pharmaceuticals MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside322.3% Upside$15.75 Price TargetShort InterestHealthy3.97% of Float Sold ShortDividend StrengthN/ASustainability-0.53Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($4.18) to ($4.57) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.17 out of 5 starsMedical Sector363rd out of 983 stocksPharmaceutical Preparations Industry172nd out of 486 stocks 3.5 Analyst's Opinion Consensus RatingSyros Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $15.75, Syros Pharmaceuticals has a forecasted upside of 322.3% from its current price of $3.73.Amount of Analyst CoverageSyros Pharmaceuticals has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.97% of the float of Syros Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverSyros Pharmaceuticals has a short interest ratio ("days to cover") of 5.8.Change versus previous monthShort interest in Syros Pharmaceuticals has recently decreased by 4.90%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldSyros Pharmaceuticals does not currently pay a dividend.Dividend GrowthSyros Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSyros Pharmaceuticals has received a 75.40% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physical health" product. See details.Environmental SustainabilityThe Environmental Impact score for Syros Pharmaceuticals is -0.53. Previous Next 0.6 News and Social Media Coverage Search Interest11 people have searched for SYRS on MarketBeat in the last 30 days. This is an increase of 175% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Syros Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders10.45% of the stock of Syros Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions48.77% of the stock of Syros Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Syros Pharmaceuticals are expected to decrease in the coming year, from ($4.18) to ($4.57) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Syros Pharmaceuticals is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Syros Pharmaceuticals is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSyros Pharmaceuticals has a P/B Ratio of 0.72. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Syros Pharmaceuticals (NASDAQ:SYRS) StockSyros Pharmaceuticals, Inc. engages in the development of gene control therapies for cancer and diseases. Its product candidates include SY-1425, SY-2101, and SY-5609. The company was founded by Richard A. Young, Nathanael S. Gray, and James E. Bradner on November 9, 2011 and is headquartered in Cambridge, MA.Read More Receive SYRS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Syros Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address SYRS Stock News HeadlinesMay 25, 2023 | finance.yahoo.comSyros Presents Data from Phase 1/1b Clinical Trial of SY-5609 in Advanced Solid Tumors at ASCO Annual MeetingMay 25, 2023 | finance.yahoo.comOne Syros Pharmaceuticals Insider Raised Stake By 212% In Previous YearJune 4, 2023 | Legacy Research (Affiliate) (Ad)“Amazon Loophole” could hand you $28,544 in “royalty” payoutsThanks to a little-known IRS loophole… Regular Americans can collect up to $28,544 (or more) in payouts from what Brad Thomas calls the “Amazon secret royalty program…” See how to collect the next payout before the strict cutoff deadline.May 25, 2023 | finance.yahoo.comOne Syros Pharmaceuticals Insider Raised Stake By 212% In Previous Year \May 23, 2023 | fool.comSyros Pharmaceuticals (NASDAQ: SYRS)May 22, 2023 | americanbankingnews.comStockNews.com Begins Coverage on Syros Pharmaceuticals (NASDAQ:SYRS)May 17, 2023 | americanbankingnews.comQ2 2023 EPS Estimates for Syros Pharmaceuticals, Inc. Increased by HC Wainwright (NASDAQ:SYRS)May 16, 2023 | americanbankingnews.comBrookline Capital Management Comments on Syros Pharmaceuticals, Inc.'s Q2 2023 Earnings (NASDAQ:SYRS)June 4, 2023 | Behind the Markets (Ad)WARNING TO ALL U.S. INVESTORSMay 16, 2023... The Day That Will Financially Paralyze 181 Million American Investors... Here are 3 steps to prepare yourself >>>May 15, 2023 | americanbankingnews.comSyros Pharmaceuticals, Inc. (NASDAQ:SYRS) Receives Average Recommendation of "Moderate Buy" from AnalystsMay 14, 2023 | americanbankingnews.comJMP Securities Cuts Syros Pharmaceuticals (NASDAQ:SYRS) Price Target to $15.00May 13, 2023 | finance.yahoo.comSyros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q1 2023 Earnings Call TranscriptMay 13, 2023 | americanbankingnews.comFY2026 EPS Estimates for Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Lifted by AnalystMay 12, 2023 | msn.comJMP Securities Maintains Syros Pharmaceuticals (SYRS) Market Outperform RecommendationMay 12, 2023 | msn.comHC Wainwright & Co. Reiterates Syros Pharmaceuticals (SYRS) Buy RecommendationMay 10, 2023 | finance.yahoo.comQ1 2023 Syros Pharmaceuticals Inc Earnings CallMay 10, 2023 | finance.yahoo.comSyros Reports First Quarter 2023 Financial Results and Provides a Corporate UpdateMay 9, 2023 | finance.yahoo.comSyros to Present at JMP Securities 2023 Life Sciences ConferenceMay 8, 2023 | finance.yahoo.comImmunityBio (IBRX) Stock Jumps 43.2%: Will It Continue to Soar?May 8, 2023 | americanbankingnews.comSyros Pharmaceuticals (SYRS) Set to Announce Quarterly Earnings on WednesdayMay 3, 2023 | finance.yahoo.comSyros to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023April 18, 2023 | americanbankingnews.comSyros Pharmaceuticals, Inc. (NASDAQ:SYRS) Receives $32.80 Average Target Price from AnalystsMarch 26, 2023 | americanbankingnews.comSyros Pharmaceuticals, Inc. (NASDAQ:SYRS) Given Average Rating of "Moderate Buy" by AnalystsMarch 6, 2023 | finance.yahoo.comSyros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q4 2022 Earnings Call TranscriptMarch 5, 2023 | benzinga.comSyros Pharmaceuticals Stock (NASDAQ:SYRS), Guidance and ForecastMarch 4, 2023 | seekingalpha.comSyros Pharmaceuticals, Inc. (SYRS) Q4 2022 Earnings Call TranscriptMarch 4, 2023 | finance.yahoo.comSyros Pharmaceuticals Full Year 2022 Earnings: EPS Beats Expectations, Revenues LagSee More Headlines SYRS Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SYRS Company Calendar Last Earnings5/10/2023Today6/03/2023Next Earnings (Estimated)8/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SYRS CUSIPN/A CIK1556263 Webwww.syros.com Phone(617) 744-1340FaxN/AEmployees124Year FoundedN/APrice Target and Rating Average Stock Price Forecast$15.75 High Stock Price Forecast$20.00 Low Stock Price Forecast$13.00 Forecasted Upside/Downside+322.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($9.63) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-94,650,000.00 Net Margins-485.12% Pretax Margin-754.40% Return on Equity-118.11% Return on Assets-54.16% Debt Debt-to-Equity Ratio0.37 Current Ratio7.37 Quick Ratio7.37 Sales & Book Value Annual Sales$12.37 million Price / Sales6.21 Cash FlowN/A Price / Cash FlowN/A Book Value$5.18 per share Price / Book0.72Miscellaneous Outstanding Shares20,596,000Free Float18,444,000Market Cap$76.82 million OptionableOptionable Beta1.67 Key ExecutivesNancy A. SimonianPresident, Chief Executive Officer & DirectorJason HaasChief Financial OfficerEric R. OlsonChief Scientific OfficerDavid A. RothChief Medical OfficerConley CheeChief Commercial OfficerKey CompetitorsRezoluteNASDAQ:RZLTHookipa PharmaNASDAQ:HOOKImmunicNASDAQ:IMUXSol-Gel TechnologiesNASDAQ:SLGLVallon PharmaceuticalsNASDAQ:VLONView All CompetitorsInsiders & InstitutionsAlly Bridge Group NY LLCSold 619,277 shares on 5/16/2023Ownership: 1.210%Geode Capital Management LLCBought 12,563 shares on 5/16/2023Ownership: 0.403%Price T Rowe Associates Inc. MDBought 10,400 shares on 5/15/2023Ownership: 0.109%Two Sigma Investments LPBought 3,139 shares on 5/15/2023Ownership: 0.066%CIBC Asset Management IncBought 15,398 shares on 5/12/2023Ownership: 0.075%View All Insider TransactionsView All Institutional Transactions SYRS Stock - Frequently Asked Questions Should I buy or sell Syros Pharmaceuticals stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Syros Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SYRS shares. View SYRS analyst ratings or view top-rated stocks. What is Syros Pharmaceuticals' stock price forecast for 2023? 4 analysts have issued 1 year price targets for Syros Pharmaceuticals' shares. Their SYRS share price forecasts range from $13.00 to $20.00. On average, they predict the company's share price to reach $15.75 in the next twelve months. This suggests a possible upside of 322.3% from the stock's current price. View analysts price targets for SYRS or view top-rated stocks among Wall Street analysts. How have SYRS shares performed in 2023? Syros Pharmaceuticals' stock was trading at $3.59 at the beginning of the year. Since then, SYRS stock has increased by 3.9% and is now trading at $3.73. View the best growth stocks for 2023 here. When is Syros Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023. View our SYRS earnings forecast. How were Syros Pharmaceuticals' earnings last quarter? Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) released its quarterly earnings results on Wednesday, May, 10th. The company reported ($0.85) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.12) by $0.27. The firm earned $2.95 million during the quarter, compared to analysts' expectations of $2.95 million. Syros Pharmaceuticals had a negative trailing twelve-month return on equity of 118.11% and a negative net margin of 485.12%. When did Syros Pharmaceuticals' stock split? Shares of Syros Pharmaceuticals reverse split on the morning of Monday, September 19th 2022. The 1-10 reverse split was announced on Monday, September 19th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Monday, September 19th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What is Nancy Simonian's approval rating as Syros Pharmaceuticals' CEO? 3 employees have rated Syros Pharmaceuticals Chief Executive Officer Nancy Simonian on Glassdoor.com. Nancy Simonian has an approval rating of 100% among the company's employees. This puts Nancy Simonian in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Syros Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Syros Pharmaceuticals investors own include Corbus Pharmaceuticals (CRBP), Sangamo Therapeutics (SGMO), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), ImmunoGen (IMGN), VBI Vaccines (VBIV), Amarin (AMRN), Amicus Therapeutics (FOLD), Nektar Therapeutics (NKTR) and Pfizer (PFE). When did Syros Pharmaceuticals IPO? (SYRS) raised $60 million in an initial public offering (IPO) on Thursday, June 30th 2016. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers. What is Syros Pharmaceuticals' stock symbol? Syros Pharmaceuticals trades on the NASDAQ under the ticker symbol "SYRS." Who are Syros Pharmaceuticals' major shareholders? Syros Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include CHI Advisors LLC (3.76%), Ally Bridge Group NY LLC (1.21%), BlackRock Inc. (0.92%), ExodusPoint Capital Management LP (0.60%), Geode Capital Management LLC (0.40%) and Price T Rowe Associates Inc. MD (0.11%). Insiders that own company stock include Eric R Olson, Eric R Olson, Richard A Young, Srinivas Akkaraju and Timothy Tyson. View institutional ownership trends. How do I buy shares of Syros Pharmaceuticals? Shares of SYRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Syros Pharmaceuticals' stock price today? One share of SYRS stock can currently be purchased for approximately $3.73. How much money does Syros Pharmaceuticals make? Syros Pharmaceuticals (NASDAQ:SYRS) has a market capitalization of $76.82 million and generates $12.37 million in revenue each year. The company earns $-94,650,000.00 in net income (profit) each year or ($9.63) on an earnings per share basis. How many employees does Syros Pharmaceuticals have? The company employs 124 workers across the globe. How can I contact Syros Pharmaceuticals? Syros Pharmaceuticals' mailing address is 35 Cambridge Park Drive 4th Floor, CAMBRIDGE MA, 02139. The official website for the company is www.syros.com. The company can be reached via phone at (617) 744-1340 or via email at hannahd@sternir.com. This page (NASDAQ:SYRS) was last updated on 6/4/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Syros Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.